Page 16 - Read Online

Cox et al. J Cancer Metastasis Treat 2021;7:25 https://dx.doi.org/10.20517/2394-4722.2021.55 Page 11 of 11

18
44. Garibaldi C, Ronchi S, Cremonesi M, et al. Interim F-FDG PET/CT during chemoradiation therapy in the management of head and
neck cancer patients: a systematic review. Int J Radiat Oncol Biol Phys 2017;98:555-73. DOI PubMed
45. Martens RM, Noij DP, Ali M, et al. Functional imaging early during (chemo)radiotherapy for response prediction in head and neck
squamous cell carcinoma; a systematic review. Oral Oncol 2019;88:75-83. DOI PubMed
46. Bonomo P, Merlotti A, Olmetto E, et al. What is the prognostic impact of FDG PET in locally advanced head and neck squamous cell
carcinoma treated with concomitant chemo-radiotherapy? Eur J Nucl Med Mol Imaging 2018;45:2122-38. DOI PubMed PMC
47. Hentschel M, Appold S, Schreiber A, et al. Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional
control and overall survival in patients with head and neck cancer. Eur J Nucl Med Mol Imaging 2011;38:1203-11. DOI PubMed
48. Kim S, Oh S, Kim JS, et al. Prognostic value of FDG PET/CT during radiotherapy in head and neck cancer patients. Radiat Oncol J
2018;36:95-102. DOI PubMed PMC
49. Lin P, Min M, Lee M, et al. Nodal parameters of FDG PET/CT performed during radiotherapy for locally advanced mucosal primary
head and neck squamous cell carcinoma can predict treatment outcomes: SUVmean and response rate are useful imaging biomarkers.
Eur J Nucl Med Mol Imaging 2017;44:801-11. DOI PubMed
50. Min M, Lin P, Lee MT, et al. Prognostic role of metabolic parameters of (18)F-FDG PET-CT scan performed during radiation therapy
in locally advanced head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging 2015;42:1984-94. DOI PubMed PMC
51. Chen SW, Hsieh TC, Yen KY, et al. Interim FDG PET/CT for predicting the outcome in patients with head and neck cancer.
Laryngoscope 2014;124:2732-8. DOI PubMed
52. Min M, Lin P, Lee M, et al. Prognostic value of 2-[(18)F] fluoro-2-deoxy-D-glucose positron emission tomography-computed
tomography scan carried out during and after radiation therapy for head and neck cancer using visual therapy response interpretation
criteria. Clin Oncol (R Coll Radiol) 2016;28:393-401. DOI PubMed
53. Morgan HE, Sher DJ. Adaptive radiotherapy for head and neck cancer. Cancers Head Neck 2020;5:1. DOI PubMed PMC
54. Geets X, Tomsej M, Lee JA, et al. Adaptive biological image-guided IMRT with anatomic and functional imaging in pharyngo-
laryngeal tumors: impact on target volume delineation and dose distribution using helical tomotherapy. Radiother Oncol 2007;85:105-
15. DOI PubMed
55. Castelli J, Simon A, Louvel G, et al. Impact of head and neck cancer adaptive radiotherapy to spare the parotid glands and decrease the
risk of xerostomia. Radiat Oncol 2015;10:6. DOI PubMed PMC
56. Vorwerk H, Zink K, Schiller R, et al. Protection of quality and innovation in radiation oncology: the prospective multicenter trial the
German Society of Radiation Oncology (DEGRO-QUIRO study). Evaluation of time, attendance of medical staff, and resources
during radiotherapy with IMRT. Strahlenther Onkol 2014;190:433-43. DOI PubMed
57. Chen L, Liang X, Shen C, Jiang S, Wang J. Synthetic CT generation from CBCT images via deep learning. Med Phys 2020;47:1115-
25. DOI PubMed PMC
58. van Dijk LV, Van den Bosch L, Aljabar P, et al. Improving automatic delineation for head and neck organs at risk by Deep Learning
Contouring. Radiother Oncol 2020;142:115-23. DOI PubMed
59. Madani I, Duprez F, Boterberg T, et al. Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and
neck cancer. Radiother Oncol 2011;101:351-5. DOI PubMed
60. Berwouts D, Olteanu LA, Duprez F, et al. Three-phase adaptive dose-painting-by-numbers for head-and-neck cancer: initial results of
the phase I clinical trial. Radiother Oncol 2013;107:310-6. DOI PubMed
61. Gouw ZAR, La Fontaine MD, Vogel WV, van de Kamer JB, Sonke JJ, Al-Mamgani A. Single-center prospective trial investigating
the feasibility of serial FDG-PET guided adaptive radiation therapy for head and neck cancer. Int J Radiat Oncol Biol Phys
2020;108:960-8. DOI PubMed
18
62. Berwouts D, Madani I, Duprez F, et al. Long-term outcome of F-fluorodeoxyglucose-positron emission tomography-guided dose
painting for head and neck cancer: Matched case-control study. Head Neck 2017;39:2264-75. DOI PubMed
63. Fleury B, Thariat J, Barnoud R, et al. Microscopic extensions of head and neck squamous cell carcinomas: impact for clinical target
volume definition. Cancer Radiother 2014;18:666-71. DOI PubMed
64. Ligtenberg H, Jager EA, Caldas-Magalhaes J, et al. Modality-specific target definition for laryngeal and hypopharyngeal cancer on
FDG-PET, CT and MRI. Radiother Oncol 2017;123:63-70. DOI PubMed
65. Grégoire V, Evans M, Le QT, et al. Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal,
hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC,
HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG
consensus guidelines. Radiother Oncol 2018;126:3-24. DOI PubMed
66. Bristow RG, Alexander B, Baumann M, et al. Combining precision radiotherapy with molecular targeting and immunomodulatory
agents: a guideline by the American Society for Radiation Oncology. Lancet Oncol 2018;19:e240-51. DOI PubMed
67. Lee N, Schoder H, Beattie B, et al. Strategy of using intratreatment hypoxia imaging to selectively and safely guide radiation dose de-
escalation concurrent with chemotherapy for locoregionally advanced human papillomavirus-related oropharyngeal carcinoma. Int J
Radiat Oncol Biol Phys 2016;96:9-17. DOI PubMed PMC
68. Troost EG, Bussink J, Hoffmann AL, Boerman OC, Oyen WJ, Kaanders JH. 18F-FLT PET/CT for early response monitoring and dose
escalation in oropharyngeal tumors. J Nucl Med 2010;51:866-74. DOI PubMed
69. Hoeben BA, Troost EG, Span PN, et al. 18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell
carcinoma is an early predictor of outcome. J Nucl Med 2013;54:532-40. DOI PubMed